利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

606 records (took 0.045 seconds)

    SIGNALLING SYSTEM
    5.
    发明申请
    SIGNALLING SYSTEM 审中-公开
    信号系统

    公开(公告)号：WO2017137759A1

    公开(公告)日：2017-08-17

    申请号：PCT/GB2017/050341

    申请日：2017-02-10

    Applicant: AUTOLUS LIMITED

    Inventor： PULÉ, Martin ,  CORDOBA, Shaun ,  THOMAS, Simon ,  ONUOHA, Shimobi ,  STAVROU, Maria

    IPC: C07K14/725

    CPC classification number: C07K14/7051 ,  C07K14/245 ,  C07K14/70521 ,  C07K14/70578 ,  C07K2319/03 ,  C07K2319/21 ,  C07K2319/33 ,  C07K2319/43 ,  C07K2319/70

    Abstract: The present invention provides a chimeric antigen receptor (CAR) system comprising; (i) a receptor component comprising a antigen binding domain and a first binding domain; and (ii) a signalling component comprising a signalling domain and a second binding domain which binds the single domain binder of the first binding domain of the receptor component wherein either the first or second binding domains comprises truncated TetR, and wherein, binding of the first and second binding domains is disrupted by the presence of an agent, such that in the absence of the agent, the receptor component and the signalling component heterodimerize and binding of the antigen binding domain to antigen results in signalling through the signalling domain; whereas in the presence of the agent, the receptor component and the signalling component do not heterodimerize and binding of the antigen binding domain to antigen does not result in signalling through the signalling domain.

    Abstract translation: 本发明提供了一种嵌合抗原受体（CAR）系统，其包含： （i）包含抗原结合结构域和第一结合结构域的受体组分; 和（ii）包含信号结构域和结合受体组分的第一结合结构域的单结构域结合剂的信号传导组分，其中第一或第二结合结构域包含截短的TetR，并且其中第一 并且第二结合结构域被药剂的存在破坏，使得在不存在药剂的情况下，受体组分和信号传导成分异二聚化并且抗原结合结构域与抗原的结合导致通过信号传导域的信号传导; 而在试剂存在下，受体组分和信号传导组分不会异二聚化，并且抗原结合域与抗原的结合不会导致通过信号传导域的信号传导。

    T20 CONSTRUCTS FOR ANTI-HIV (HUMAN IMMUNODEFICIENCY VIRUS) THERAPY AND/OR VACCINES
    10.
    发明申请
    T20 CONSTRUCTS FOR ANTI-HIV (HUMAN IMMUNODEFICIENCY VIRUS) THERAPY AND/OR VACCINES 审中-公开
    T20抗艾滋病毒（人类免疫缺陷病毒）治疗和/或疫苗的建议

    公开(公告)号：WO2016191481A1

    公开(公告)日：2016-12-01

    申请号：PCT/US2016/034129

    申请日：2016-05-25

    Applicant: IMMUNOMEDICS, INC.

    Inventor： STENLER, Sofia ,  WAHREN, Britta ,  CHANG, Chien-Hsing ,  GOLDENBERG, David M.

    IPC: C07K14/16 ,  A61K38/16 ,  A61P31/18

    CPC classification number: A61K39/21 ,  A61K39/12 ,  A61K39/42 ,  A61K45/06 ,  A61K48/00 ,  A61K2039/5154 ,  A61K2039/53 ,  A61K2039/55561 ,  C07K2319/70 ,  C12N2740/16122 ,  C12N2740/16134

    Abstract: The present invention concerns methods and compositions for treatment of HIV infection using a T20 expression vector, such as that shown in SEQ ID NO:1 or SEQ ID NO:3. The T20 expression vector may be used in a variety of therapeutic applications, such as ex vivo transfection of dendritic cells to induce a host immune response to HIV, localized transfection in vivo in a gene therapy approach to provide longer term delivery of T20, or in vitro production of T20 peptide. The T20 may be secreted into the circulation to act as a fusion inhibitor of HIV infection, or may induce an endogenous immune response to HIV or HIV-infected cells. Alternatively, a DDD peptide may be incorporated in a fusion protein comprising T20 or another antigenic protein or peptide to enhance the immune response to the protein or peptide.

    Abstract translation: 本发明涉及使用T20表达载体如SEQ ID NO：1或SEQ ID NO：3所示的用于治疗HIV感染的方法和组合物。 T20表达载体可用于多种治疗应用，例如体外转染树突状细胞以诱导宿主对HIV的免疫应答，在基因治疗方法中局部转染体内以提供T20的更长期递送，或 体外生产T20肽。 T20可能分泌到循环中，作为HIV感染的融合抑制剂，或者可能诱导对HIV或HIV感染细胞的内源性免疫应答。 或者，可以将DDD肽掺入到包含T20或另一抗原蛋白或肽的融合蛋白中，以增强对蛋白质或肽的免疫应答。

Patent Agency Ranking